Novel Guillain-Barré drug disables part of immune system
A first-of-its-kind drug for Guillain-Barré syndrome works by selectively switching off a specific part of the immune system. This targeted approach offers a new treatment option for the rare autoimmune disorder, which attacks the peripheral nerves. The innovation matters because current therapies are broad and often have severe side effects.